Hepatitis C can be cured: Will hepatitis B become next?

Чуланов В. П., Зуева А. П., Костюшев Д. С., Брезгин С. А., Волчкова Е. В., Малеьев В. В.

Терапевтический архив

Т. 89, Вып. 11, С. 4-13

Опубликовано: 2017

Тип ресурса: Обзор

DOI:10.17116/terarkh201789114-13

Аннотация:

Chronic hepatitis B (CHB) and C (CHC) are one of the leading causes of cirrhosis and liver cancer with over a million of people dying annually from their consequences. In Russia CHB and CHC morbidity and related mortality show an upward trend. As a result of recent breakthroughs in antiviral therapeutics CHC became a curable disease. Modern therapeutics effectively suppress viral r eplication in CHB patients, but withdrawal of antivirals usually results in disease relapse. Loss of HBsAg required for the so called "functional cure" is a very rare event. Moreover, "complete cure" when the virus is entirely eliminated from the body is not possible due to a persistent form of covalently closed circular DNA (cccDNA) of hepatitis B virus (HBV) in hepatocytes refractory to modern antivirals. Today, there is a plethora of new promising medications being at different stages of development that target different steps of viral life cycle, including inhibitors of interaction between HBV and its en

Ключевые слова:

Chronic hepatitis B; Covalently closed circular DNA; CRISPR/Cas9; Gene therapy; Hepatitis B virus; Immunotherapy; MiRNA; Molecular therapy

antivirus agent; chronic hepatitis B; chronic hepatitis C; gene therapy; human; immunotherapy; procedures; Antiviral Agents; Genetic Therapy; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Immunotherapy

Язык текста: Русский

ISSN: 2309-5342

Чуланов В. П. Владимир Петрович 1970-

Зуева А. П.

Костюшев Д. С.

Брезгин С. А.

Волчкова Е. В. Елена Васильевна 1953-

Малеьев В. В.

Chulanov V. P. Vladimir Petrovich 1970-

Zueva A. P.